Medical Developments International share price charges higher on Mundipharma deal

The Medical Developments International Ltd (ASX:MVP) share price has charged higher after announcing a deal with Mundipharma…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Medical Developments International Ltd (ASX: MVP) share price has charged higher this morning following the release of a positive announcement.

At the time of writing the healthcare company's shares are up almost 4% to $5.29.

What was announced?

This morning Medical Developments International announced that it has reached an agreement with Mundipharma for the exclusive distribution rights of its key Penthrox pain management product in Australia.

According to the release, the agreement will see Mundipharma provide its salesforce and marketing experience, whereas Medical Developments International will continue to maintain relationships within the key ambulance channel and support Mundipharma with their marketing endeavours.

The agreement contains minimum volumes which guarantee current turnover in Australia but with significant forecast upside.

Medical Developments International's CEO, John Sharman, believes this is a great deal for the company.

He said: "This is an exciting deal for MVP because Mundipharma has a respected presence in the pain market with broad sales force coverage across Australia. This presence in the field is expected to lead to impressive sales growth in the short to medium term, particularly within General Practitioner and Hospital channels."

Mundipharma Australia and New Zealand's managing director, Jane Orr, was equally pleased with the deal.

She said: "Options for pain relief are limited in many clinical settings, particularly GP procedure rooms, so we welcome the opportunity to help address this important clinical need. Mundipharma has provided medicines for the management of pain and worked collaboratively with healthcare professionals to provide education on pain management for more than 20 years in Australia, so Penthrox is an ideal fit for our business."

Finally, Medical Developments International's chairman, David Williams, revealed that the company hopes this deal shows "international distributors the upside that is possible with a strong sales force."

Elsewhere in the healthcare sector on Monday, the Clinuvel Pharmaceuticals Limited (ASX: CUV) share price has dropped lower after the U.S. FDA delayed its PDUFA date for its SCENESSE product and the Starpharma Holdings Limited (ASX: SPL) share price is higher after signing a second oncology agreement with AstraZeneca.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Starpharma Holdings Limited. The Motley Fool Australia has recommended Medical Developments International Limited and Starpharma Holdings Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Silhouettes of nine people climbing a steep mountain to the top at sunset, and helping each other along the way.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors had a wild ride this Thursday.

Read more »

Excited couple celebrating success while looking at smartphone.
Share Gainers

Why Domino's, NRW, Pro Medicus, and WIA Gold shares are charging higher today

These shares are avoiding the market weakness and are pushing higher today. But why?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Healthcare Shares

UP 127% in a year, why is the Pro Medicus share price rocketing higher again today?

ASX investors are sending Pro Medicus shares flying higher on Thursday. But why?

Read more »

Happy man working on his laptop.
Share Gainers

Here are the top 10 ASX 200 shares today

The ASX roared higher this hump day.

Read more »

Delighted adult man, working on a company slogan, on his laptop.
Share Gainers

2 popular ASX 200 shares that returned 30%-plus in FY25

These popular stocks rewarded their owners in FY25.

Read more »

A cool dude looks back at the camera while ziplining above the treetops.
Share Gainers

How these 3 ASX 200 stocks turned a $10K investment into more than $60,000 in just 3 years!

These fast-rising ASX 200 stocks could be on their way to 10-bagger status.

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Share Gainers

Why Civmec, Dexus, James Hardie, and Magellan shares are storming higher today

These shares are having a good session on hump day. But why?

Read more »

A bland looking man in a brown suit opens his jacket to reveal a red and gold superhero dollar symbol on his chest.
Share Gainers

These were the best ASX 200 shares to buy in June

Big returns were delivered by these shares last month. But why?

Read more »